End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25 CAD | +1.46% | +0.36% | +10.28% |
06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
06-28 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ABBVIE INC. | Other Pharmaceuticals | +1.46% | +0.36% | +10.28% | +28.07% | - | 303B | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- ABBV Stock
- ABBV Stock
- Charts AbbVie Inc.
- Comparison Chart